Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer:: Overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5

被引:47
作者
Horak, P
Pils, D
Kaider, A
Pinter, A
Elandt, K
Sax, C
Zielinski, CC
Horvat, R
Zeillinger, R
Reinthaller, A
Krainer, M
机构
[1] Med Univ Vienna, Div Clin Oncol, Dept Internal Med 1, A-1090 Vienna, Austria
[2] Med Univ Vienna, Core Unit Med Stat & Informat, Sect Clin Biometr, A-1090 Vienna, Austria
[3] Med Univ Vienna, Dept Gynecol & Obstet, A-1090 Vienna, Austria
[4] Med Univ Vienna, Dept Clin Pathol, A-1090 Vienna, Austria
关键词
D O I
10.1158/1078-0432.CCR-05-1276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Epithelial ovarian cancer is the most common cause of mortality from gynecologic malignancies. Due to advanced stage at diagnosis, most patients need systemic treatment in addition to surgery. Tumor necrosis factor (TNF) - related apoptosis-inclucing ligand (TRAIL) is a member of the TNF family with a promising toxicity profile and synergistic activity with chemotherapeutic agents. Experimental Design: We used an arrayed panel of epithelial ovarian cancer tissue to assess the protein expression of TRAIL and the clinically most relevant members of its pathway death receptors 4 and 5 (DR4 and DR5) and the long form of FLICE inhibitory protein (FLIPL) Results: We could show that a majority (66.2%) of the tumor tissues displayed either reduced DR4/DR5 expression (20.6%), increased FLIPL expression (39.7%), or both (5.9%) as determined by immunohistochemistry. Furthermore, higherTRAIL expression in the surrounding connective tissue but not in the tumor cells is significantly (P < 0.05) linked with favorable overall survival in advanced-stage patients. Conclusions: Mechanisms to escape the immune surveillance mediated byTRAIL are developed by ovarian cancer cells in a high percentage. TRAIL expression in the ovarian cancer microenvironment has an effect on overall survival. These findings enhance our understanding of ovarian cancer pathology and might be helpful in guiding TRAIL-based therapy in future.
引用
收藏
页码:8585 / 8591
页数:7
相关论文
共 35 条
[1]   Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma [J].
Arts, HJG ;
de Jong, S ;
Hollema, H ;
ten Hoor, K ;
van der Zee, AGJ ;
de Vries, EGE .
GYNECOLOGIC ONCOLOGY, 2004, 92 (03) :794-800
[2]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[3]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[4]   TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].
Bodmer, JL ;
Holler, N ;
Reynard, S ;
Vinciguerra, P ;
Schneider, P ;
Juo, P ;
Blenis, J ;
Tschopp, J .
NATURE CELL BIOLOGY, 2000, 2 (04) :241-243
[5]   Cancer of the ovary [J].
Cannistra, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2519-2529
[6]   Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4 [J].
Chuntharapai, A ;
Dodge, K ;
Grimmer, K ;
Schroeder, K ;
Marsters, SA ;
Koeppen, H ;
Ashkenazi, A ;
Kim, KJ .
JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :4891-4898
[7]  
FATHALLA MF, 1971, LANCET, V2, P163
[8]   Defective death receptor signaling as a cause of tumor immune escape [J].
French, LE ;
Tschopp, J .
SEMINARS IN CANCER BIOLOGY, 2002, 12 (01) :51-55
[9]  
Griffith TS, 1998, J IMMUNOL, V161, P2833
[10]  
Griffith TS, 1999, J IMMUNOL, V162, P2597